Full-Time

Senior Clinical Research Director

Ophthalmology

Confirmed live in the last 24 hours

Deadline 8/20/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$225k - $375k/yr

Senior, Expert

Cambridge, MA, USA + 1 more

More locations: Morristown, NJ, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Risk Management
Requirements
  • Medical Doctor (MD) and ophthalmology residency training required
  • More than 7 years of clinical trial and/or clinical development experience
  • Fluent in English (verbal and written)
Responsibilities
  • Provide ophthalmology focused medical and scientific expertise to the cross functional project team to conduct the clinical studies from early phases to LCM programs
  • Establish clinical development strategy and lead clinical team, collaborate with other medical and clinical scientific experts, clinical development scientists, in the project in collaboration with the Global safety Officer, Regulatory Strategist and other key functional representatives to deliver development strategy and prepare/assist with regulatory agency interactions
  • Develop or contribute to the regulatory documentation for the project(s), provide clinical leadership to other operational development activities pertaining to study start-up (e.g. pressure test, competitive intelligence, patient engagement, cluster feasibility, study risk assessment)
  • Provide appropriate medical input & clinical leadership for all activities related to study conduct such as responses to IRBs and HA questions, protocol scientific and medical training, medical review of data within the scope of the centralized monitoring, clinical and medical information for the study team, medical advisors/Clinical Project Leaders from Clinical Study Units, and investigators
  • Responsible for the clinical part of regulatory documents, Common Technical Document for submission to regulatory bodies (FDA, EMA, PMDA) and answers to questions from health authorities
  • Serve as the medical expert in the Clinical Study team, ensuring the medical relevance of the clinical data and able to act as mentor for other clinical team members, has the capacity to train them on the medical/scientific strategy by indication
  • Designs the global clinical development strategy and generates the Clinical Development Plan (in close cooperation with other members of the team, particularly Regulatory Affairs and Health Economics); adjusts and updates the strategy according to the project progression and information available
  • Leads the clinical development including planned life cycle management (LCM)
  • Ongoing assessment of the product benefit–risk profile during development and LCM, in strong collaboration with pharmacovigilance and clinical operations team
  • Implements strategies to identify, monitor and resolve clinical program/trial issues
  • Responsible for medical monitoring for a study or clinical program as well as reviewing and monitoring study data
  • Provide appropriate medical input & support for all activities related to clinical studies such as medical training, feasibility, medical review of data, documents, medical information/communications for the study team and other stakeholders
  • Prepares/reviews key clinical documents such as: meeting requests and briefing packages for Regulatory agencies, extended synopsis/protocol for clinical trials, Investigator Brochure, Clinical Trial Authorization dossier (IMPD, IND), summary of clinical efficacy and clinical overview of the Common Technical Document (CTD)
  • Provides clinical input to Statistical Analysis Plans (SAP), Target Product Profile (TPP) and Risk Management Plan
  • Writes/reviews answers to clinical questions from Health Authorities and IRB/Ethics Committees and investigators
  • Reviews Key Results Memos, Clinical Study Reports as well as scientific publications and communications on the project
  • Lead the medical/clinical assessment of license-in opportunities, as needed
  • Manage other study physicians (CRDs) and clinical scientists in the same program, as needed
  • Author or co-author manuscripts and abstracts
  • Establishes and maintains appropriate collaborations with key opinion leaders or advisory boards
  • Serves as clinical team leader/representative at the global project team(s), regulatory agency meetings, Steering committees, benefit-risk assessment committee, and at the submission task force.
Desired Qualifications
  • Board certified or eligible in Ophthalmology
  • Strong scientific and academic background with deep understanding of retina and eye diseases
  • Clinical trial or pharmaceutical experience in ophthalmology
  • Knowledge of drug development, ocular gene therapy, regulatory strategy
  • Good networking ability in cross-cultural environment
  • Strong interpersonal, communication, presentation, and negotiation skills across all levels of the organization
  • Performance oriented with ability to work along agreed timelines and a focus on strategy and execution
  • Outstanding communicator. Excellent problem-solving, conflict-resolution and decision-making skills

Sanofi provides healthcare solutions through its focus on pharmaceuticals and biotechnology. The company develops treatments and vaccines aimed at addressing medical needs in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are made available to patients, healthcare professionals, and governments. The company emphasizes research and development, investing in scientific innovation to create new therapies and improve existing ones. Unlike many competitors, Sanofi has a strong global presence and collaborates with other healthcare organizations to enhance its product offerings. The main goal of Sanofi is to improve health outcomes and the quality of life for people worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The approval of Dupixent for chronic spontaneous urticaria opens new market opportunities.
  • Sanofi's innovative on-body injector for Sarclisa enhances patient treatment experience.

What critics are saying

  • Integration challenges from acquisitions may disrupt operations and delay synergies.
  • Increased competition in immunology could impact Sanofi's market share.
  • Reliance on key products like Dupixent poses revenue risks if market conditions change.

What makes Sanofi unique

  • Sanofi's robust R&D pipeline focuses on immunology, oncology, and rare diseases.
  • The company leverages strategic acquisitions to expand its portfolio and capabilities.
  • Sanofi's global reach allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.